In this work, we explored the possibility of targeting storage of FXa in platelets for the treatment of hemophilia with inhibitors, with inspiration from previous work on other bypassing agents and the recent work on the zymogen‐like FXa showing better therapeutic efficacy than FVIIa in HA and HB mice.13, 35. The gene discussed is F10; the disease is hemophilia.